Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-shorter: FEC3-D3 vs AC4-D4 in Neoadjuvant Breast Cancer
NCT02001506Phase 3Completed
- Sponsor
- Asan Medical Center
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, epirubicin, cyclophosphamide, docetaxel in breast cancer, sponsored by Asan Medical Center. Started Nov 2012; status: completed.
02
Drugs
fluorouracilepirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02001506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02001506.